Santhera

News

Santhera shores up funding ahead of vamorolone verdict

Swiss biotech Santhera has raised CHF 22 million ($23.5 million) in bridge financing that it says will allow it to fund its operations through to October, when the FDA is

News

Santhera seeks speedy FDA review of Duchenne drug vamorolone

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.

News

Buoyed by new data, Santhera preps filing for DMD drug vamor...

A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone.

Disease Spotlight

Living with LHON: Individual struggles, common challenges

Being diagnosed with a rare disease is often a bolt from the blue, and while each person’s journey is different, there are common challenges that bind patient communities together.

Views & Analysis

Living with LHON: Sight loss won’t stop James from seeing th...

When he was first told he had LHON, a rare genetic disease that would rob him of his sight, James Ferguson’s first thought was that it would also rob him of his identity.

Disease Spotlight